The publication is seeking financial support from its readers to maintain its operations. Declining advertising revenue has created a funding shortfall, threatening the continuation of its independent and unbiased journalism. Readers who value the publication’s reporting are encouraged to contribute. Their support will help ensure the availability of accurate and meaningful news for all.
In response to a national security investigation launched April 1st, President Trump plans to announce pharmaceutical tariffs within the next two weeks. These tariffs aim to incentivize the repatriation of pharmaceutical production to the United States, significantly impacting countries like Britain and Ireland, which boast large pharmaceutical trade surpluses with the U.S. The impending tariffs are particularly concerning for major UK-based pharmaceutical companies like GSK and AstraZeneca, who have already engaged in intense lobbying efforts to mitigate potential losses. While a previous 10% tariff on most imports was temporarily averted for pharmaceuticals, this new announcement suggests a more aggressive protectionist strategy.
President Trump announced an impending “major” tariff on imported pharmaceuticals, aiming to encourage domestic production. He further asserted that Taiwan Semiconductor Manufacturing Company (TSMC) faces a potential 100% tax if it doesn’t establish U.S. plants, criticizing a $6.6 billion government grant to TSMC as unnecessary. These actions reflect Trump’s broader strategy to bolster American manufacturing and reduce reliance on foreign goods. The pharmaceutical tariff and TSMC pressure tactics represent significant policy shifts with potentially far-reaching economic consequences.
John Q. Hosedrinker